VIEWING TIME: 5 minutes
“As we have seen in the AAN and other meetings, data using different biomarkers, whether optical coherence tomography, serum neurofilament light, other biological markers, volumetric MRI, other MRI markers plus researchers, what is the topic We are seeing that neurodegeneration occurs from the beginning of the disease process, if not probably before the patient realizes it or the providers are even aware of the diagnosis.I would say that instead of two At different stages, we now see them almost overlapping.
In the three decades since the first therapies for multiple sclerosis (MS) were introduced in the 1990s, much progress has been made in the development of effective and disease-modifying therapies (DMT) for the disease. New approaches are now being explored, such as those aimed at inhibiting Bruton’s tyrosine kinase (BTK) inhibition, or those with varied dosing options, to improve other aspects of disease management. especially the quality of life.
Despite this progress in improving treatments, many patients still use old drugs. This can often be related to your condition, or to reduce the risk of unwanted side effects or other reasons. Shared decision-making between patient and physician helps achieve one goal of treatment: optimization. This has also spurred conversations about induction and escalation strategies for DMT use, and although the field seems to lean more toward induction, starting with aggressive, highly effective treatment, a better understanding of the pathology of the disease has darkened the waters a little.
For Robert K. Shin, MD, professor of neurology, MedStar Georgetown University Hospital, the conversation about the state of MS treatment reflects a change in thinking from the field. In a conversation with NeurologyLive®, he talked about the changes in thinking that have taken place since the 1990s and what trends are emerging in the approach to disease management.